Amgen to Make Significant Investment in Manufacturing, R&D and Commercial Operations Expansion
Amgenannounced that it anticipates significant investment in additional manufacturing and R&D operations in the United States and Europe and expansion of its commercial operations into new markets.
In Cork, Ireland, Amgen intends to invest more than $1 billion in new process development, bulk manufacturing and fill and finish facilities that will give the company capacity closer to the patients it serves in Europe. Amgen currently is adding a manufacturing plant in Puerto Rico to produce EPOGEN(R) (Epoetin alfa) and Aranesp(R) (darbepoetin alfa). In 2005, Amgen received licensure of a NEUPOGEN(R) (Filgrastim) and Neulasta(R) (pegfilgrastim) plant in Puerto Rico and an Enbrel(R) (etanercept) plant in Rhode Island, and announced plans to acquire Abgenix, Inc., a leading biopharmaceutical company with a large manufacturing plant in Fremont, California.
Amgen also announced it intends to expand its existing research and development operations in Cambridge, Mass., San Francisco, Seattle, and Cambridge, U.K., and build a new development center in Uxbridge, U.K. In addition, Amgen has moved its European headquarters from Lucerne to Zug, Switzerland, and formed a new entity, Amgen International, also located in Zug, that is expected to enhance access to Amgen's vital medicines for patients in emerging markets in Central and Southeast Asia, Africa and Latin America.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
